Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gottlieb Initiative Will Expedite Device, Drug Pain Control Alternatives, FDA Chief Says

Executive Summary

US FDA Chief Scott Gottlieb said he will soon announce an initiative to help expedite approvals of both innovative devices and drugs that are designed to control pain as an alternative to opioid prescriptions commonly written by doctors.

You may also be interested in...



FDA Issues Challenge To Medtech To Fight Opioid Crisis

Echoing President Trump's ongoing call to fight the opioid-abuse epidemic, the US agency is asking medtech companies to submit applications for new products to tackle the issue. Promising devices and diagnostic tools identified by the agency will get extra attention from FDA, but they won't have to submit an additional application for a Breakthrough Device designation.

Bills Advancing In US Congress Would Hasten FDA Reviews Of Non-Opioid Medtech Alternatives

The Senate Health, Education, Labor and Pensions (HELP) Committee and House Energy and Commerce Health Subcommittee each passed bills this week to expedite approval pathways for non-opioid devices and drugs to control pain and prevent further addictions. Other opioid bills passed by the House subpanel seek to remove reimbursement challenges for opioid-alternative pain control devices.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel